On October 29, 2019 Vectura Group plc (LSE: VEC) ("Vectura", the "Group", or the "Company"), is reported the appointment of Will Downie as CEO and Executive Director of the Company with effect from 7th November 2019 (Press release, Vectura, OCT 29, 2019, View Source [SID1234549984]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Prior to joining Vectura, Will spent ten years as the Senior Vice President, Global Sales and Marketing at Catalent Inc., one of the world’s largest Contract Development and Manufacturing Organisations (CDMO).
In his role at Catalent, Will led the commercial effort and had responsibility for global sales, marketing and commercial operations activities. During his tenure, he developed an outstanding track record in helping drive the long-term growth of the company as well as positioning Catalent as one of the leading brands in the pharmaceutical services space. He has a deep understanding of the development and advanced drug delivery market and has amassed significant experience in driving sustained long-term results, as well as building performance-focused organisations and meeting customer needs on a global scale.
Prior to Catalent, Will held positions as Vice President & General Manager, Global Molecular Imaging at GE Healthcare, Vice President Sales EMEA at Amersham Health and Director of Business Development and Commercial Operations at Quintiles Innovex UK Limited. In his early career, he worked in a range of sales and marketing management positions at both Sanofi and Merck & Co.
Bruno Angelici, Chairman, commented: "I am very pleased to welcome Will Downie as Vectura’s new CEO. He brings a wealth of relevant experience which will help Vectura to grow and deliver on its new strategic focus as a leading inhaled CDMO business.
"I would like to thank Paul Fry for the significant work he has done since stepping into the Interim Chief Executive role and driving the change necessary for Vectura to become a leading player in the inhaled CDMO space. Paul will resume his responsibilities as Chief Financial Officer from 7th November."
Will Downie commented: "I am delighted to have accepted the role of CEO of Vectura and to have the opportunity to expand and build on its reputation as an inhalation device and formulation specialist. I am looking forward to driving the new business strategy and ensuring the Company achieves its long-term goal of becoming a world class CDMO organisation in the inhalation space."
There are no additional details to disclose under Listing Rule 9.6.13 (1) to (6) in respect of the appointment of Will Downie.
-Ends-
For more information, please contact:
Vectura Group plc
David Ginivan – VP Corporate Communications +44 (0)7471 352 720
Elizabeth Knowles – VP Investor Relations +44 (0)7767 160 565
Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart / David Daley +44 (0)20 3709 5700